Trial Profile
Effect of PCSK9-Antibody (Alirocumab) on Dyslipidemia Secondary to Nephrotic Syndrome
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 22 Aug 2022
Price :
$35
*
At a glance
- Drugs Alirocumab (Primary) ; Atorvastatin
- Indications Dyslipidaemias
- Focus Therapeutic Use
- 02 Oct 2020 Status changed from recruiting to discontinued.
- 25 Jan 2017 Status changed from active, no longer recruiting to recruiting.
- 13 Jan 2017 Status changed from not yet recruiting to active, no longer recruiting.